OncoMatch/Clinical Trials/NCT07114367
NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
Is NCT07114367 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies NB02 (Poseltinib) for non hodgkin lymphoma (nhl).
Treatment: NB02 (Poseltinib) — This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: BTK inhibitor (NB02, ibrutinib, acalabrutinib, zanubrutinib)
Exception: patients who discontinued treatment due to adverse-effect-related intolerance or for economic or social reasons remain eligible for enrollment
Patients who have previously been treated with NB02 (poseltinib) or any other BTK inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib). Patients who have experienced progression on BTKi mono or BTKi containing regimen (However, patients who discontinued treatment due to adverse-effect-related intolerance or for economic or social reasons remain eligible for enrollment).
Lab requirements
Blood counts
adequate organ function including
Kidney function
adequate organ function including
Liver function
adequate organ function including
Adequate organ function including
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify